Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
NCT ID: NCT02649478
Last Updated: 2018-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1430 participants
INTERVENTIONAL
2014-08-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)
NCT03535870
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
NCT04746040
BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients
NCT03394989
A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
NCT04466176
A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
NCT04462822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The secondary objectives of the study are:
* To demonstrate statistical superiority of generic fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder to placebo.
* To demonstrate statistical superiority of Advair 100/50 to placebo.
* To investigate the safety and tolerability of fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder compared with Advair 100/50 in the target population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fluticasone / Salmeterol
fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler ("LOMI") inhaler device twice a day by inhalation throughout the study
Fluticasone / Salmeterol
Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
Advair Diskus 100/50
Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
Advair Diskus 100/50
Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
placebo inhaler
placebo inhaled powder twice a day by inhalation throughout the study
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluticasone / Salmeterol
Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
Placebo
Advair Diskus 100/50
Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be able to provide written informed consent or, in the case of adolescents, informed assent in addition to an informed consent form signed by the adolescent's parent(s) or legal guardian(s).
3. Be current non-smokers and also may not have used tobacco products (e.g., cigarettes, cigars, pipe tobacco) within the year prior to Visit 1, and have 10 years or less (10 pack-years for cigarettes) of historical use.
4. Have persistent asthma, as defined by the National Asthma Education and Prevention Program, for at least 12 weeks before Visit 1.
5. The forced expiratory volume at one second ("FEV1") range required for enrollment is dependent on whether the subject is an adult or adolescent and whether he or she is currently treated with inhaled corticosteroids ("ICS") at Visit 1
6. Demonstrate 15% or greater reversibility of FEV1 between 10 and 30 minutes following 360 µg of albuterol inhalation. NOTE: If the subject does not meet criterion 6 at Visit 1 (Day -14), this criterion must be met at Visit 2 (Day -1).
7. Be able to discontinue controller asthma medication (including leukotriene modifiers ("LTM"), ICS and long acting β-agonists (LABAs)) during the Run-in Period and Treatment Period.
8. Be able to replace current short-acting β-agonists (SABAs) with the study-supplied albuterol (or equivalent) rescue medication inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for a least 6 hours before lung function assessments during study visits).
9. Be appropriately using 1 of the following asthma-treatment regimens and meet the associated criteria:
* Low- to medium-dose ICS for at least 4 weeks before Visit 1, with or without an adjunctive asthma therapy (i.e., LABA, LTM, or theophylline). Both the ICS dose and overall daily asthma regimen must have been stable for the 4 weeks before Visit 1; or
* Leukotriene modifier (such as montelukast, zafirlukast, or pranlukast) or theophylline as monotherapy at a stable dose for at least 4 weeks before Visit 1;or
* Daily (or near daily) rescue medication (e.g., albuterol/ salbutamol or other inhaled SABA used to treat acute asthma) in the 4 weeks before Visit 1.
10. Must not have been treated (for any reason) with oral or parenteral corticosteroids for at least 1 month before Visit 1 and must not have used oral SABAs for at least 12 hours before Visit 1 and for the remainder of the study. Routine use of oral/parenteral corticosteroids and oral SABAs is not allowed after Visit 1.
11. Subjects may continue using short-acting forms of theophylline (withheld at least 12 hours before a site visit), twice daily controlled release forms of theophylline (withheld at least 24 hours before a site visit), and once daily controlled-release forms of theophylline (withheld at least 36 hours before a site visit).
12. Be able to answer questions regarding asthma status and be able to document) device usage and asthma status on a twice daily basis.
NOTE: Placebo inhaler use (i.e., compliance) must be at least 75% of the planned doses taken as assessed at Visit 2, for the subject to be considered eligible to continue in the study.
13. Demonstrate proper use of metered dose inhaler ("MDI") and dry-powder inhaler devices.
Exclusion Criteria
2. Are unable to discontinue ICS, LABA, or LTM.
3. Have a history of life-threatening asthma, defined as an asthma episode (at any time in the past) associated with any of the following: respiratory arrest or intubation, hypercapnia, hypoxic seizures, or syncopal episode.
4. Have exercise-induced asthma as the only asthma-related diagnosis that does not require daily asthma control medicine.
5. Have evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
6. Have current clinical evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, or other respiratory abnormalities other than asthma.
7. Have obstructive sleep apnea severe enough to require biphasic or continuous positive-airway pressure therapy, or likely to interfere with the assessment of asthma symptoms, in the investigator's judgment.
8. Using medication with the potential to affect the course of asthma or interact with sympathomimetic amines (e.g., β blockers \[including eye drops\], oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors).
9. Had a viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks before Visit 1 or have an infection during the Run-in Period.
10. Participated in an interventional study or used any investigational drug for any disease within 30 days (or 4 half lives, if this is longer than 30 days) before Visit 1 before Visit 1.
11. Used an anti-immunoglobulin E (e.g., omalizumab) or any other monoclonal antibody for any reason within 6 months before Visit 1.
12. Are hypersensitive to any β2-agonist sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy or any component of these combination medications including severe milk protein hypersensitivity.
13. Are exhibiting any factors (e.g., infirmity, disability, or geographic location, inability to follow instructions or study compliance requirements) that the investigator believes would likely limit the subject's compliance with the study protocol or scheduled site visits. This includes recent history of substance abuse or uncontrolled psychiatric or neurological behavior that would render the subject incapable of reliably following study requirements, in the judgment of the investigator.
14. Have an affiliation with the participating site; in other words, subject may not be an immediate family member of any study site staff and may not be employed directly or indirectly by the study site.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vectura Limited
INDUSTRY
Roxane Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Roxane Laboratories Research Site #30
Glendale, Arizona, United States
Roxane Laboratories Research Site #46
Phoenix, Arizona, United States
Roxane Laboratories Research Site #1
Surprise, Arizona, United States
Roxane Laboratories Research Site #13
Tempe, Arizona, United States
Roxane Laboratories Research Site #84
Bakersfield, California, United States
Roxane Laboratories Research Site #72
Costa Mesa, California, United States
Roxane Laboratories Research Site #67
Encinitas, California, United States
Roxane Laboratories Research Site #4
Fountain Valley, California, United States
Roxane Laboratories Research Site #64
Fullerton, California, United States
Roxane Laboratories Research Site #3
Huntington Beach, California, United States
Roxane Laboratories Research Site #70
Huntington Beach, California, United States
Roxane Laboratories Research Site #92
Huntington Beach, California, United States
Roxane Laboratories Research Site #38
Irvine, California, United States
Roxane Laboratories Research Site #91
Lincoln, California, United States
Roxane Laboratories Research Site #59
Los Angeles, California, United States
Roxane Laboratories Research Site #16
Los Angeles, California, United States
Roxane Laboratories Research Site #90
Los Angeles, California, United States
Roxane Laboratories Research Site #6
Mission Viejo, California, United States
Roxane Laboratories Research Site #78
Rolling Hills Estates, California, United States
Roxane Laboratories Research Site #98
Sacramento, California, United States
Roxane Laboratories Research Site #53
San Diego, California, United States
Roxane Laboratories Research Site #93
San Diego, California, United States
Roxane Laboratories Research Site #28
San Jose, California, United States
Roxane Laboratories Research Site #60
Santa Monica, California, United States
Roxane Laboratories Research Site #33
Centennial, Colorado, United States
Roxane Laboratories Research Site #43
Denver, Colorado, United States
Roxane Laboratories Research Site #63
Denver, Colorado, United States
Roxane Laboratories Research Site #21
Wheat Ridge, Colorado, United States
Roxane Laboratories Research Site #50
Hialeah, Florida, United States
Roxane Laboratories Research Site #11
Hialeah, Florida, United States
Roxane Laboratories Research Site #66
Homestead, Florida, United States
Roxane Laboratories Research Site #83
Jupiter, Florida, United States
Roxane Laboratories Research Site #8
Miami, Florida, United States
Roxane Laboratories Research Site #23
Miami, Florida, United States
Roxane Laboratories Research Site #86
Miami, Florida, United States
Roxane Laboratories Research Site #89
Miami, Florida, United States
Roxane Laboratories Research Site #20
Miami, Florida, United States
Roxane Laboratories Research Site #68
Miami, Florida, United States
Roxane Laboratories Research Site #80
Miami, Florida, United States
Roxane Laboratories Research Site #54
Miami, Florida, United States
Roxane Laboratories Research Site #12
Miami, Florida, United States
Roxane Laboratories Research Site #74
North Miami Beach, Florida, United States
Roxane Laboratories Research Site #35
Orlando, Florida, United States
Roxane Laboratories Research Site #17
Orlando, Florida, United States
Roxane Laboratories Research Site #94
Port Orange, Florida, United States
Roxane Laboratories Research Site #34
Lilburn, Georgia, United States
Roxane Laboratories Research Site #51
Rincon, Georgia, United States
Roxane Laboratories Research Site #79
Normal, Illinois, United States
Roxane Laboratories Research Site #47
River Forest, Illinois, United States
Roxane Laboratories Research Site #100
Brownsburg, Indiana, United States
Roxane Laboratories Research Site #62
Baltimore, Maryland, United States
Roxane Laboratories Research Site #52
Baltimore, Maryland, United States
Roxane Laboratories Research Site #71
Bethesda, Maryland, United States
Roxane Laboratories Research Site #96
Silver Spring, Maryland, United States
Roxane Laboratories Research Site #81
Fall River, Massachusetts, United States
Roxane Laboratories Research Site #56
North Dartmouth, Massachusetts, United States
Roxane Laboratories Research Site #55
Ann Arbor, Michigan, United States
Roxane Laboratories Research Site #97
Chelsea, Michigan, United States
Roxane Laboratories Research Site #5
Plymouth, Minnesota, United States
Roxane Laboratories Research Site #85
St Louis, Missouri, United States
Roxane Laboratories Research Site #32
Bellevue, Nebraska, United States
Roxane Laboratories Research Site #25
Bellevue, Nebraska, United States
Roxane Laboratories Research Site #36
Omaha, Nebraska, United States
Roxane Laboratories Research Site #57
Las Vegas, Nevada, United States
Roxane Laboratories Research Site #10
Atco, New Jersey, United States
Roxane Laboratories Research Site #65
Skillman, New Jersey, United States
Roxane Laboratories Research Site #7
New York, New York, United States
Roxane Laboratories Research Site #2
New York, New York, United States
Roxane Laboratories Research Site #41
Clemmons, North Carolina, United States
Roxane Laboratories Research Site #45
Raleigh, North Carolina, United States
Roxane Laboratories Research Site #31
Cincinnati, Ohio, United States
Roxane Laboratories Research Site #95
Columbus, Ohio, United States
Roxane Laboratories Research Site #24
Hilliard, Ohio, United States
Roxane Laboratories Research Site #61
Middleburg Heights, Ohio, United States
Roxane Laboratories Research Site #73
Toledo, Ohio, United States
Roxane Laboratories Research Site #14
Edmond, Oklahoma, United States
Roxane Laboratories Research Site #15
Oklahoma City, Oklahoma, United States
Roxane Laboratories Research Site #37
Eugene, Oregon, United States
Roxane Laboratories Research Site #40
Medford, Oregon, United States
Roxane Laboratories Research Site #58
Portland, Oregon, United States
Roxane Laboratories Research Site #26
Warwick, Rhode Island, United States
Roxane Laboratories Research Site #99
Warwick, Rhode Island, United States
Roxane Laboratories Research Site #69
Greenville, South Carolina, United States
Roxane Laboratories Research Site #22
Spartanburg, South Carolina, United States
Roxane Laboratories Research Site #19
Smyrna, Tennessee, United States
Roxane Laboratories Research Site #27
Boerne, Texas, United States
Roxane Laboratories Research Site #75
Dallas, Texas, United States
Roxane Laboratories Research Site #49
El Paso, Texas, United States
Roxane Laboratories Research Site #44
Houston, Texas, United States
Roxane Laboratories Research Site #77
Lewisville, Texas, United States
Roxane Laboratories Research Site #87
Plano, Texas, United States
Roxane Laboratories Research Site #29
San Antonio, Texas, United States
Roxane Laboratories Research Site #48
San Antonio, Texas, United States
Roxane Laboratories Research Site #42
West Jordan, Utah, United States
Roxane Laboratories Research Site #39
South Burlington, Vermont, United States
Roxane Laboratories Research Site #9
Henrico, Virginia, United States
Roxane Laboratories Research Site #88
Richmond, Virginia, United States
Roxane Laboratories Research Site #18
Richmond, Virginia, United States
Roxane Laboratories Research Site #76
Tacoma, Washington, United States
Roxane Laboratories Research Site #82
Greenfield, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FLSA-P100/50-PVCL-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.